Epigral Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.6 pts less than Nifty Microcap 250 and 7.1 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Epigral Limited reported Q1 FY26 revenue from operations of Rs. 606.54 crore, down from Rs. 651.20 crore in Q1 FY25 (a decline of about 6.9% year-on-year). Profit before tax fell to Rs. 106.73 crore from Rs. 131.10 crore, pressured by higher finance costs (Rs. 23.37 crore vs Rs. 14.25 crore) and higher depreciation (Rs. 41.54 crore vs Rs. 33.45 crore). Reported standalone PAT jumped to Rs. 160.41 crore from Rs. 86.01 crore, but this is almost entirely driven by a one-time deferred tax credit of Rs. 80.87 crore from opting for the lower Section 115BAA tax regime. EPS stood at Rs. 37.18. The board also approved raising up to Rs. 400 crore through non-convertible debentures or other debt instruments in one or more tranches. The company entered into a related-party investment with promoter-linked Prozeal Green Power entities to set up a 19.80 MW wind-solar hybrid power plant, with a 20-year power purchase commitment. Auditor SRBC & Co LLP issued a clean limited review with no qualifications.
Core operating performance weakened this quarter with revenue and EBITDA both contracting, while finance costs and depreciation surged—signaling rising debt and capex burden. The headline PAT surge is non-recurring due to the tax regime change, so underlying profitability is softer than it appears. The proposed Rs. 400 crore debt raise and related-party power deal may further increase leverage but secures long-term power supply.